Log in

NASDAQ:VLRX - Valeritas Stock Price, Forecast & News

-0.04 (-2.56 %)
(As of 12/6/2019 04:00 PM ET)
Today's Range
Now: $1.52
50-Day Range
MA: $1.47
52-Week Range
Now: $1.52
Volume36,005 shs
Average Volume291,242 shs
Market Capitalization$12.66 million
P/E RatioN/A
Dividend YieldN/A
Valeritas Holdings, Inc, a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States. The company offers V-Go, a wearable insulin delivery device for basal-bolus therapy. It also develops V-Go Prefill that is in the design-development stage for eliminating the device-filling process and the need for EZ fill refrigeration for patients with Type 2 diabetes; and V-Go SIM for real-time tracking information of basal and bolus dosing utilization. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Current SymbolNASDAQ:VLRX



Sales & Book Value

Annual Sales$26.40 million
Book Value$2.86 per share


Net Income$-45,930,000.00
Net Margins-183.82%


Market Cap$12.66 million
Next Earnings Date3/3/2020 (Estimated)
OptionableNot Optionable

Receive VLRX News and Ratings via Email

Sign-up to receive the latest news and ratings for VLRX and its competitors with MarketBeat's FREE daily newsletter.

Valeritas (NASDAQ:VLRX) Frequently Asked Questions

What is Valeritas' stock symbol?

Valeritas trades on the NASDAQ under the ticker symbol "VLRX."

How were Valeritas' earnings last quarter?

Valeritas Holdings Inc (NASDAQ:VLRX) issued its quarterly earnings results on Tuesday, November, 12th. The company reported ($1.91) EPS for the quarter, beating analysts' consensus estimates of ($2.52) by $0.61. The company had revenue of $8.46 million for the quarter. Valeritas had a negative return on equity of 1,142.30% and a negative net margin of 183.82%. View Valeritas' Earnings History.

When is Valeritas' next earnings date?

Valeritas is scheduled to release their next quarterly earnings announcement on Tuesday, March 3rd 2020. View Earnings Estimates for Valeritas.

What guidance has Valeritas issued on next quarter's earnings?

Valeritas updated its FY 2019 After-Hours earnings guidance on Monday, November, 25th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $$31.5-31.8 million, compared to the consensus revenue estimate of $$32.05 million.

What price target have analysts set for VLRX?

2 brokerages have issued twelve-month price objectives for Valeritas' shares. Their forecasts range from $12.00 to $14.00. On average, they anticipate Valeritas' stock price to reach $13.00 in the next year. This suggests a possible upside of 755.3% from the stock's current price. View Analyst Price Targets for Valeritas.

What is the consensus analysts' recommendation for Valeritas?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Valeritas in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Valeritas.

Has Valeritas been receiving favorable news coverage?

Media stories about VLRX stock have trended neutral recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Valeritas earned a news sentiment score of 0.2 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Valeritas.

Who are some of Valeritas' key competitors?

What other stocks do shareholders of Valeritas own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Valeritas investors own include TherapeuticsMD (TXMD), Tandem Diabetes Care (TNDM), Verastem (VSTM), Adamis Pharmaceuticals (ADMP), Exelixis (EXEL), Rexahn Pharmaceuticals (REXN), TRACON Pharmaceuticals (TCON), TG Therapeutics (TGTX), Trevena (TRVN) and Veritone (VERI).

Who are Valeritas' key executives?

Valeritas' management team includes the folowing people:
  • Mr. John E. Timberlake, Pres, CEO & Director (Age 54)
  • Mr. Erick J. Lucera CPA, CFA, CFO & Sec. (Age 51)
  • Mr. Geoffrey H. Jenkins, Exec. VP of Manufacturing, Operations and R&D (Age 67)
  • Dr. Matthew H. Nguyen, Chief Commercial Officer (Age 49)
  • Mr. Scott A. Huie, VP of Regulatory Affairs/Quality Assurance and Compliance

When did Valeritas IPO?

(VLRX) raised $60 million in an initial public offering (IPO) on Thursday, March 23rd 2017. The company issued 6,000,000 shares at $9.00-$11.00 per share. Cowen and Company and Wedbush PacGrow acted as the underwriters for the IPO and Roth Capital Partners and B. Riley & Co. were co-managers.

Who are Valeritas' major shareholders?

Valeritas' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Millennium Management LLC (0.65%). Company insiders that own Valeritas stock include Armistice Capital Master Fund, John Edward Timberlake, Joseph M Mandato, Matt Nguyen and Peter Devlin. View Institutional Ownership Trends for Valeritas.

Which major investors are buying Valeritas stock?

VLRX stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC. Company insiders that have bought Valeritas stock in the last two years include Armistice Capital Master Fund, John Edward Timberlake, Joseph M Mandato, Matt Nguyen and Peter Devlin. View Insider Buying and Selling for Valeritas.

How do I buy shares of Valeritas?

Shares of VLRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Valeritas' stock price today?

One share of VLRX stock can currently be purchased for approximately $1.52.

How big of a company is Valeritas?

Valeritas has a market capitalization of $12.66 million and generates $26.40 million in revenue each year. The company earns $-45,930,000.00 in net income (profit) each year or ($34.20) on an earnings per share basis. Valeritas employs 125 workers across the globe.View Additional Information About Valeritas.

What is Valeritas' official website?

The official website for Valeritas is http://www.valeritas.com/.

How can I contact Valeritas?

Valeritas' mailing address is 750 ROUTE 202 SOUTH SUITE 600, BRIDGEWATER NJ, 08807. The company can be reached via phone at 908-927-9920 or via email at [email protected]

MarketBeat Community Rating for Valeritas (NASDAQ VLRX)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  238 (Vote Outperform)
Underperform Votes:  136 (Vote Underperform)
Total Votes:  374
MarketBeat's community ratings are surveys of what our community members think about Valeritas and other stocks. Vote "Outperform" if you believe VLRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VLRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/7/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel